510(k) Report

FDA applicant

Accriva Diagnostics, Inc.

San Diego, CA3 decisions2019–20231 recall

FDA records 3 decisions for Accriva Diagnostics, Inc. (San Diego, CA) from 2019 to 2023: 3 510(k) clearances. Most are in product codes JPA (System, Multipurpose For In Vitro Coagulation…) and FMK (Single Use Only Blood Lancet With An Integral…). Its devices cite 7 predicates, 1 of them its own earlier devices. 1 recall is linked to its devices.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) refreshed weekly, last Nov 3, 2026

FIG. A — Illustration, hematology panel, where it files most

How often FDA has decided Accriva Diagnostics, Inc.’s devices, and how often a recall has named them.

FDA decisions per year

1in 2023

2019: 12021: 12023: 1
2019high 1 (2019) · low 0 (2020)2026

2026 so far, outlined.

Recalls per year

1in 2026

2026 (partial year): 1
2019high 1 (2026) · low 0 (2019)2026

Class I Class II/III not classified

FIG. 1 — Accriva Diagnostics, Inc. by year, 2019–2026Sources: FDA decision databases, recall and enforcement reports · Data through Oct 25, 2026

Planning a device like Accriva Diagnostics, Inc.’s? A 510(k) Report ranks candidate predicates for your device by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report